{"commentary":{"count":11,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":4,"x_thread":4,"podcast":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01824875\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT01824875","nct_id":"NCT01824875","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct01824875. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.","label":"Arm A (temozolomide)","type":"EXPERIMENTAL"},{"description":"Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.","label":"Arm B (temozolomide and capecitabine)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2026-05-26","type":"ACTUAL"},"conditions":["Gastrinoma","Glucagonoma","Insulinoma","Islet Cell Carcinoma","Pancreatic Polypeptide Tumor","Recurrent Islet Cell Carcinoma","Somatostatinoma"],"enrollment":{"count":144,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"temozolomide","type":"DRUG"},{"name":"capecitabine","type":"DRUG"}],"last_update":"2026-09-29","lead_sponsor":"ECOG-ACRIN Cancer Research Group","official_title":"A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-05-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival","timeFrame":"Assessed every 3 months for 3 years and then every 6 months for years 3-5"}],"references":[{"citation":"Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Suarez CJ, Martin BA, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski MM, Schmulbach EL, Reidy-Lagunes DL, Strosberg JR, O'Dwyer PJ, Benson AB 3rd. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023 Mar 1;41(7):1359-1369. doi: 10.1200/JCO.22.01013. Epub 2022 Oct 19.","pmid":"36260828","type":"DERIVED"}],"start_date":{"date":"2013-08-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors","url":"https://clinicaltrials.gov/study/NCT01824875"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct01824875"}